Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Salarius Pharmaceuticals, Inc. (SLRX)

1.72   0.07 (4.24%) 06-06 15:18
Open: 1.6499 Pre. Close: 1.65
High: 1.8 Low: 1.62
Volume: 99,895 Market Cap: 6(M)

Technical analysis

as of: 2023-06-06 2:51:13 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 2.22     One year: 2.69
Support: Support1: 1.25    Support2: 1.03
Resistance: Resistance1: 1.9    Resistance2: 2.3
Pivot: 1.49
Moving Average: MA(5): 1.56     MA(20): 1.49
MA(100): 1.97     MA(250): 3.13
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 86.6     %D(3): 80.3
RSI: RSI(14): 57.8
52-week: High: 7.19  Low: 1.07
Average Vol(K): 3-Month: 102 (K)  10-Days: 42 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SLRX ] has closed Bollinger Bands are 55% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.65 - 1.66 1.66 - 1.67
Low: 1.54 - 1.55 1.55 - 1.56
Close: 1.6 - 1.61 1.61 - 1.63

Company Description

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Headline News

Thu, 11 May 2023
Salarius: Q1 Earnings Snapshot - Houston - Chron

Thu, 11 May 2023
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update - Yahoo Finance

Tue, 09 May 2023
Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood - MarketWatch

Tue, 09 May 2023
Salarius Pharmaceuticals Inc (SLRX) Stock: What Does the Chart Say Tuesday? - InvestorsObserver

Thu, 20 Apr 2023
Salarius Pharmaceuticals Presents Compelling Data in Two SP ... - GlobeNewswire

Tue, 04 Apr 2023
Salarius Pharmaceuticals to Present at the Diamond Equity ... - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 3 (M)
Shares Float 2 (M)
% Held by Insiders 7.6 (%)
% Held by Institutions 10.3 (%)
Shares Short 95 (K)
Shares Short P.Month 128 (K)

Stock Financials

EPS -15.56
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.25
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -61.2
Return on Equity (ttm) -158.3
Qtrly Rev. Growth 0
Gross Profit (p.s.) -4.73
Sales Per Share 0
EBITDA (p.s.) -6.66
Qtrly Earnings Growth 0
Operating Cash Flow -17 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -0.11
PEG Ratio 0
Price to Book value 0.75
Price to Sales 0
Price to Cash Flow -0.34

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.